Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: J. P. Desilles, C. Gregoire, C. Le Cossec, J. Lambert, O. Mophawe, M. R. Losser, F. Lambiotte, S. Le Tacon, M. Cantier, N. Engrand, P. Trouiller, J. Pottecher
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMC 2020-06-01
Sarja:Trials
Aiheet:
COVID-19
Randomised controlled trial
Lung damage
Neutrophil extracellular traps
ARDS
Dornase alfa
Linkit:http://link.springer.com/article/10.1186/s13063-020-04488-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia